CLINICAL ASSESSMENT OF ANTIBIOTICS USED IN CHRONIC KIDNEY DISEASE: A LONGITUDINAL OBSERVATIONAL STUDY
DOI:
https://doi.org/10.22159/ijpps.2024v16i10.52103Keywords:
Chronic kidney disease, Creatine clearance, Antibiotics, Clinical assessmentAbstract
Objective: The study was conducted to clinically evaluate the safety and efficacy of antibiotic drug consumption based on laboratory data, specifically White Blood Cells(WBC) and Glomerular Filtration Rate (GFR) before and after antibiotic use in patients with chronic kidney disease.
Methods: This retro-prospective longitudinal study was conducted on 115 patients with Chronic Kidney Disease(CKD) based on 6 months of data at a tertiary care teaching institute, Geetanjali Medical College and Hospital, in Udaipur, Rajasthan. Inclusion criteria were all the patients who were admitted in the nephrology department and were above 18 years, who were receiving antibiotics, and Creatine Clearance(CrCl) was ≤ 60ml/min were included into this study. Exclusion criteria patients with renal replacement and lacking information of laboratory data (WBC, CrCl) and those who were below the age of 18 were excluded from the study. The data were analysed using descriptive analysis.
Results: The mean age of the CKD patients was 50.10 (standard deviation=17.47) years. Males were found in greater numbers than that of females with 66 (58%) and 49(42%) respectively. Patients admitted with stage 5 CKD (66%) were greater than the patients with stage 4 CKD. 10 different types of antibiotics were provided to CKD patients, of which seven had irrational doses. Piptaz, Meropenem, and Teicoplanin have the highest irrational doses incidence.
Conclusion: Patients with CKD Stages 4 and 5 were given systemic antibiotics at unreasonable dosages, most frequently in the forms of piptaz, aztreonam, and meropenem injections. The incidence of irrational antibiotic dosages provided to the CKD patients was still high.
Downloads
References
National Kidney Foundation and National Kidney Foundation. Kidney Disease Outcomes Quality Initiative, Clinical practice guidelines for chronic kidney disease : evaluation, classification and stratification.
J. Coresh, B. C. Astor, T. Greene, G. Eknoyan, and A. S. Levey, “Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey,” Am J Kidney Dis, vol. 41, no. 1, pp. 1–12, Jan. 2003, doi: 10.1053/AJKD.2003.50007.
R. S. Barsoum, “Chronic Kidney Disease in the Developing World,” New England Journal of Medicine, vol. 354, no. 10, pp. 997–999, Mar. 2006, doi: 10.1056/NEJMP058318/ASSET/77165629-6753-4384-A8C6-586A60CD12C4/ASSETS/IMAGES/LARGE/NEJMP058318_F1.JPG.
S. J. Hwang, J. C. Tsai, and H. C. Chen, “Epidemiology, impact and preventive care of chronic kidney disease in Taiwan,” Nephrology, vol. 15, no. SUPPL. 2, pp. 3–9, Jun. 2010, doi: 10.1111/J.1440-1797.2010.01304.X.
L. S. Hooi et al., “A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia,” Kidney Int, vol. 84, no. 5, pp. 1034–1040, Nov. 2013, doi: 10.1038/KI.2013.220.
M. J. Sarnak and B. L. Jaber, “Mortality caused by sepsis in patients with end-stage renal disease compared with the general population,” Kidney Int, vol. 58, no. 4, pp. 1758–1764, Oct. 2000, doi: 10.1111/J.1523-1755.2000.00337.X.
M. Restinia, H. Lucida, and W. G. S, “A Study on Clinical Assessment of Antibiotic Used in Chronic Kidney Disease Patients,” JURNAL ILMU KEFARMASIAN INDONESIA, vol. 15, no. 2, p. 203, Sep. 2017, doi: 10.35814/jifi.v15i2.521.
A. Ishani, A. J. Collins, C. A. Herzog, and R. N. Foley, “Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 Study,” Kidney Int, vol. 68, no. 1, pp. 311–318, Jul. 2005, doi: 10.1111/J.1523-1755.2005.00414.X.
M. AHMED, P. KUMAR, D. V. KISHORE, P. KUMAR, R. KAUSER, and M. ALI, “RATIONALE OF ANTIBIOTIC PRESCRIPTION IN PATIENTS VISITING A TERTIARY CARE SOUTH INDIAN HOSPITAL,” Asian Journal of Pharmaceutical and Clinical Research, vol. 14, pp. 27–30, Dec. 2021, doi: 10.22159/AJPCR.2021.V14I12.36082.
M. Al-Aloul, H. Miller, S. Alapati, P. A. Stockton, M. J. Ledson, and M. J. Walshaw, “Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use,” Pediatr Pulmonol, vol. 39, no. 1, pp. 15–20, Jan. 2005, doi: 10.1002/PPUL.20138.
A. S. Levey et al., “National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,” Ann Intern Med, vol. 139, no. 2, Jul. 2003, doi: 10.7326/0003-4819-139-2-200307150-00013/ASSET/IMAGES/13TT9.JPG.
C. L. Long, M. A. Raebel, D. W. Price, and D. J. Magid, “Compliance with Dosing Guidelines in Patients with Chronic Kidney Disease,” http://dx.doi.org/10.1345/aph.1D399, vol. 38, no. 5, pp. 853–858, May 2004, doi: 10.1345/APH.1D399.
H. J. Manley, C. A. Cannella, G. R. Bailie, and W. L. St. Peter, “Medication-Related Problems in Ambulatory Hemodialysis Patients: A Pooled Analysis,” American Journal of Kidney Diseases, vol. 46, no. 4, pp. 669–680, Oct. 2005, doi: 10.1053/J.AJKD.2005.07.001.
M. Y. MUNAR and H. SINGH, “Drug Dosing Adjustments in Patients with Chronic Kidney Disease,” Am Fam Physician, vol. 75, no. 10, pp. 1487–1496, May 2007, Accessed: Jul. 03, 2024. [Online]. Available: https://www.aafp.org/pubs/afp/issues/2007/0515/p1487.html
L. S. Dalrymple and A. S. Go, “Epidemiology of acute infections among patients with chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 5, pp. 1487–1493, Sep. 2008, doi: 10.2215/CJN.01290308.
G. Stemer and R. Lemmens-Gruber, “Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: A systematic literature review,” BMC Nephrol, vol. 12, no. 1, pp. 1–12, Jul. 2011, doi: 10.1186/1471-2369-12-35/TABLES/5.
“Medscape Registration.” Accessed: Jul. 15, 2024. [Online]. Available: https://emedicine.medscape.com/article/238798-overview?form=fpf
S. Lueangarun and A. Leelarasamee, “Impact of Inappropriate Empiric Antimicrobial Therapy on Mortality of Septic Patients with Bacteremia: A Retrospective Study,” Interdiscip Perspect Infect Dis, vol. 2012, p. 13, 2012, doi: 10.1155/2012/765205.
K. L. Cavanaugh, “Diabetes Management Issues for Patients With Chronic Kidney Disease,” Clinical Diabetes, vol. 25, no. 3, pp. 90–97, Jul. 2007, doi: 10.2337/DIACLIN.25.3.90.
S. Steigerwalt, “Management of Hypertension in Diabetic Patients With Chronic Kidney Disease,” Diabetes Spectrum, vol. 21, no. 1, pp. 30–36, Jan. 2008, doi: 10.2337/DIASPECT.21.1.30.
A. ALI, P. KUMAR, J. A. ANSARI, M. FATIMA, and F. IRRUM, “A PROSPECTIVE OBSERVATIONAL STUDY ON MEDICATION USE PATTERN IN PATIENTS WITH RISK FACTORS OF CHRONIC KIDNEY DISEASE,” Asian Journal of Pharmaceutical and Clinical Research, vol. 14, pp. 144–148, Dec. 2021, doi: 10.22159/AJPCR.2021.V14I12.43513.
A. Kumar et al., “Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock,” Chest, vol. 136, no. 5, pp. 1237–1248, Nov. 2009, doi: 10.1378/CHEST.09-0087.
E. Leung, D. E. Weil, M. Raviglione, and H. Nakatani, “The WHO policy package to combat antimicrobial resistance,” Bull World Health Organ, vol. 89, no. 5, pp. 390–392, May 2011, doi: 10.2471/BLT.11.088435.
R. O. Laing, H. V. Hogerzeil, and D. Ross-Degnan, “Ten recommendations to improve use of medicines in developing countries,” Health Policy Plan, vol. 16, no. 1, pp. 13–20, 2001, doi: 10.1093/HEAPOL/16.1.13.
Published
How to Cite
Issue
Section
Copyright (c) 2024 RAO DILIP SINGH, CHAUDHARY RAHUL, SOLANKI HITENDRAPAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
